Evidence map›Paper›PMID 41025074›Full record

ArticleWorld journal of gastroenterology2025

Machine learning fibrosis score for pediatric metabolic dysfunction-associated steatotic liver disease: Promising but premature.

Toshifumi Yodoshi

Abstract readEditorial
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. MASLD In Children - A Distinct Phenotype?Current obesity reports · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Toshifumi YodoshiDivision of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, United States. toshifumi.yodoshi@cchmc.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease in children, affecting up to 38% with obesity of children. With the global shift from non-alcoholic fatty liver disease (NAFLD) to MASLD using affirmative criteria (hepatic steatosis plus ≥ 1 cardiometabolic risk factor) and approximately 99% concordance in pediatrics, the development of non-invasive fibrosis tools is accelerating. Yao

Indexed as

Fatty LiverLiver CirrhosisMachine LearningNon-alcoholic Fatty Liver DiseasePediatric ObesityAdolescentBiomarkersChildHumansLiverROC CurveSeverity of Illness IndexBiomarkersCost-effectivenessEthnic diversityExternal validationHealth economicsLiver fibrosisMachine learningMetabolic dysfunction-associated steatotic liver diseaseNon-invasive biomarkersOverfitting

Identifiers

PMID41025074
PMCPMC12476683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.